Bicyclo Patents (Class 514/681)
-
Patent number: 7718706Abstract: The present invention relates to novel arylphenyl-substituted cyclic ketoenols of the formula (I) in which X represents halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro, cyano or in each case optionally substituted phenyl, phenoxy, phenylthio, phenylalkoxy or phenylalkylthio, Y represents in each case optionally substituted cycloalkyl, aryl or hetaryl, Z represents hydrogen, halogen, alkyl, alkoxy, alkenyloxy, halogenoalkyl, halogenoalkoxy, halogenoalkenyloxy, nitro or cyano, CKE represents one of the groups in which A, B, D, G and Q1 to Q6 are each as defined in the description, to a plurality of processes for their preparation and to their use as pesticides and herbicides.Type: GrantFiled: September 17, 2007Date of Patent: May 18, 2010Assignee: Bayer AktiengesellschaftInventors: Folker Lieb, Reiner Fischer, Alan Graff, Udo Schneider, Thomas Bretschneider, Christoph Erdelen, Wolfram Andersch, Mark-Wilhelm Drewes, Markus Dollinger, Ingo Wetcholowsky, Randy Allen Myers
-
Patent number: 7714023Abstract: Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, or pharmaceutically acceptable salts, solvates, polymorphs, or hydrates thereof.Type: GrantFiled: February 17, 2005Date of Patent: May 11, 2010Assignee: Sepracor Inc.Inventor: Timothy J. Barberich
-
Publication number: 20100041747Abstract: The present invention relates to the use of certain spiro, ketone and carboxylic acid compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins and the use of these compounds for the production of a cosmetic or pharmaceutical composition for the promotion of hair growth or for the treatment or prevention of inflammatory autoimmune diseases, of diseases caused by fungi, of bacterial infections, of viral infections, of diseases caused by parasites, protozoa or worms, of cancer, of diseases of cells, of fibrosing diseases, and of non-neoplastic changes and diseases which are attributable to prions and changes in the structure and function of cellular proteins and cells.Type: ApplicationFiled: August 14, 2007Publication date: February 18, 2010Applicants: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Heinrich-Heine-Universitat DusseldorfInventors: Gunter Fischer, Cordelia Schiene-Fischer, Sebastian Daum, Gerhard Küllertz, Manfred Braun
-
Publication number: 20100021566Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.Type: ApplicationFiled: July 28, 2008Publication date: January 28, 2010Inventor: David E. Winslow
-
Publication number: 20100015221Abstract: The present invention provides an orally rapid disintegrating tablet preparation that contains a high dose of a fat-soluble active ingredient, that exhibits excellent disintegration characteristics in the oral cavity, and that can be produced by a dry tabletting method. The present invention also provides a method of producing an orally rapid disintegrating tablet preparation. The present invention discloses an orally rapid disintegrating tablet preparation that is obtained by tabletting a uniform mixture prepared by mixing saccharide alcohol, crystalline cellulose, and a lubricant with a granule that has been produced by the adsorption of a fat-soluble active ingredient on a porous material.Type: ApplicationFiled: December 20, 2006Publication date: January 21, 2010Applicant: Eisai R&D Management Co.Ltd.Inventors: Norishige Takami, Shinsuke Nagira, Yasushi Okada, Noriko Okada, Takayuki Ohwaki, Reiko Nishijima
-
Publication number: 20090318391Abstract: The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and/or prevention of neoplastic diseases and disorders.Type: ApplicationFiled: July 4, 2007Publication date: December 24, 2009Applicant: TILTAN PHARMA LTD.Inventor: Shmuel A. Ben-Sasson
-
Publication number: 20090318566Abstract: The present invention relates to compounds of general formula (1): in which, independently of each other, R1 and R2 represent: —OH, or —CH2—O—R3, or —CH2—S—R3, or R3, R4, R5 and R6 representing, independently of each other, —H or a carbon-containing group with 1 to 10 carbon atoms, saturated or unsaturated, optionally substituted with one or more heteroatomic groups. The invention also relates to pharmaceutical compositions containing these compounds, and their uses, in particular in the context of the treatment of cancer.Type: ApplicationFiled: January 6, 2005Publication date: December 24, 2009Inventors: Vi-Thuy Dao, Jean De Gunzburg, Robert Michelot, Oliver Christophe De Mil
-
Publication number: 20090285865Abstract: Palatable, solid oral formulations or compositions include at least one bioactive agent capable of chemical sterilization of human and animal males. Depending on the targeted species, the bioactive formulations comprise suitable additives, excipients, water-swellable compositions, and/or processing aids and can be made into uncoated or coated forms to modulate the release profile of the bioactive agents. Among the bioactive agents are zinc compounds and complexes and organic drugs with established pharmacological activities, which are traditionally unrelated to any form of contraception.Type: ApplicationFiled: May 14, 2009Publication date: November 19, 2009Inventor: Shalaby W. Shalaby
-
Publication number: 20090253761Abstract: Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: May 21, 2009Publication date: October 8, 2009Inventors: Kevin R. Lynch, Timothy L. Macdonald
-
Publication number: 20090234022Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.Type: ApplicationFiled: March 12, 2009Publication date: September 17, 2009Applicant: Hana Biosciences, Inc.Inventors: Christopher G. Salentine, Kieran O'Donoghue
-
Publication number: 20090208433Abstract: The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses.Type: ApplicationFiled: April 30, 2007Publication date: August 20, 2009Applicant: Symrise GmbH & Co., KGInventors: Martina Herrmann, Oskar Koch, Gabriele Vielhaber, Jean Krutmann
-
Publication number: 20090192201Abstract: The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).Type: ApplicationFiled: January 28, 2008Publication date: July 30, 2009Inventor: Guillermo Selman-Housein Sosa
-
Publication number: 20090186900Abstract: There is provided a compound of Formula I wherein the various symbols are as defined in the description, and a method of manufacturing a medicament for use in the therapy of a condition or disease associated with 17?-hydroxysteroid dehydrogenase (17?-HSD), comprising a compound of Formula I.Type: ApplicationFiled: August 27, 2008Publication date: July 23, 2009Inventors: Nigel VICKER, Gillian Margaret ALLAN, Harshani Rithma Ruchiranani LAWRENCE, Joanna Mary DAY, Atul PUROHIT, Michael John REED, Barry Victor Lloyd POTTER
-
Patent number: 7563789Abstract: The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], wherein the substituents are as defined in the specification.Type: GrantFiled: April 7, 2006Date of Patent: July 21, 2009Inventors: Gloria Long Anderson, Tawfeq Abdul-Raheem Kaimari
-
Publication number: 20090175869Abstract: This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: December 10, 2008Publication date: July 9, 2009Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
-
Publication number: 20090137393Abstract: The invention relates to novel 2,4,6-trialkylphenyl-substituted cyclopentane-1,3-diones of the formula (I) in which X, Y, A, B, Q1, Q2 and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising, firstly, the 2,4,6-trialkylphenyl-substituted cyclopentane-1,3-diones of the formula (I) and, secondly, at least one crop plant compatibility-improving compound.Type: ApplicationFiled: January 3, 2007Publication date: May 28, 2009Applicant: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Dieter Feucht, Ulrich Gorgens, Olga Malsam, Alfred Angermann, Guido Bojack, Alan Graff, Christian Arnold, Thomas Auler, Martin Jeffrey Hills, Hein Kehne, Christopher Hugh Rosinger, Jan Dittgen
-
Publication number: 20090118377Abstract: The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.Type: ApplicationFiled: January 12, 2009Publication date: May 7, 2009Applicant: The Regents of the University of MichiganInventors: Shaomeng Wang, Jianyong Chen, Zaneta Nikolovska-Coleska, Dajun Yang
-
Publication number: 20090099250Abstract: The present invention describes non-steroidal compounds of the general formula (I) in which A is in which X1 means one or more groups on the phenyl ring and represents independently of one another a halogen, OH, (C1-C4)alkyl, (C1-C4)alkyl-O, (C3-C6)cycloalkyl-O, (C1-C14)acyl-O, (C1-C4)alkenyl, (C1-C4)alkynyl, perfluoro(C1-C4)alkyl radical, —CHO or CN, and X2 means one or more groups on the phenyl ring and represents independently of one another an H, halogen, OH, (C1-C4)alkyl, (C1-C4)alkyl-O, (C1-C4)alkenyl, (C1-C4)alkynyl, perfluoro-(C1-C4)alkyl radical, —CHO or CN, as Estrogens.Type: ApplicationFiled: October 10, 2008Publication date: April 16, 2009Inventors: Ralf WYRWA, Olaf Peters, Rolf Bohlmann, Peter Droescher, Katja Prelle, Karl Heinrich Fritzemeier, Hans Peter Muhn
-
Publication number: 20090062401Abstract: The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes.Type: ApplicationFiled: December 28, 2005Publication date: March 5, 2009Applicants: UNIVERSITAT DORTMUND, MAX-PLANCK-GESELLSCHAFT ZUR FODERUNG DER WISSENSCHAFTEN E.V., UNIVERSITAT BERNInventors: Alex Odermatt, Herbert Waldmann, Michael Scheck, Marcus A. Koch
-
Publication number: 20080317801Abstract: Control of Rodents A particulate mixture for use in the control of rodents which comprises a mixture of a plurality of bait particles and a plurality of non-bait particles, wherein each bait particle comprises matter edible by a rodent and a rodenticide and wherein each non-bait particle comprises matter edible by a rodent and has a flavour different from the flavour of a bait particle and wherein the non-bait particles are distinguished from the bait particles by at least one physical characteristic selected from size, shape, surface texture and internal texture. A non-bait particulate food for rodents as use in the control of rodents, when presented in admixture with bait particles to rodents, to encourage consumption of the bait particles. Such non-bait particulate food comprises dry extruded pellets of cereal meal and dried powdered crustacean.Type: ApplicationFiled: September 15, 2006Publication date: December 25, 2008Inventors: Sharon Hughes, Roland Twydell
-
Patent number: 7456223Abstract: A composition and its use for local percutaneous delivery of a drug, in particular a muscle relaxant, more particularly cyclobenzaprine present in an amount of about 1 to about 10% by weight of the composition in an organogel cream are disclosed. The composition is applied directly to the skin over accessible muscles of mastication from which it is rapidly absorbed through the skin to provide control of conditions such as bruxism and tooth clenching. The composition can also be applied to the skin overlying these muscles to control muscle hyperactivity (spasm) and/or trigger points, from other causes. The composition can be formulated to include another active agent such as a non-steroidal anti-inflammatory, for example ketoprofen.Type: GrantFiled: October 12, 2004Date of Patent: November 25, 2008Inventor: Mark H. Friedman
-
Publication number: 20080220094Abstract: The invention of this application relates to compositions and methods for the treatment and/or prevention of osteoporosis; improving and/or enhancing bone formation; and prevention and/or reducing bone mineral density loss. More particularly, the invention relates to a composition comprising vitamin K, in any form and betacryptoxanthin. A further aspect of this invention is a composition comprising vitamin K, in any form, betacryptoxanthin, and/or vitamin D and/or calcium.Type: ApplicationFiled: October 30, 2007Publication date: September 11, 2008Applicant: WyethInventors: Gregory Eugene Bobyock, Judith Diane Kendler Moreines, Lynda Sun Lee
-
Publication number: 20080200441Abstract: Selective estrogen receptor modulators, as well their related pharmaceutical compositions and methods of use, are provided herein. These estrogen receptor modulators include compounds that primarily exhibit estrogen receptor antagonist activity or primarily exhibit selective estrogen receptor antagonist and agonist activity, i.e., SERM activity, in specific tissue types. Particular embodiments provide compounds that behave as NeuroSERMs promoting neurotrophism and neuroprotection in brain tissue. These NeuroSERMs represent a subset of the modulators compounds provided herein that can cross the blood-brain-barrier and exert estrogen receptor agonist-like effects in the brain. The compounds should be useful for treating a variety of diseases, particularly estrogen receptor-mediated diseases and disorders, such as osteoporosis, breast and endometrial cancers, atherosclerosis and Alzheimer's disease.Type: ApplicationFiled: February 14, 2008Publication date: August 21, 2008Inventors: Roberta Diaz Brinton, Liqin Zhao
-
Publication number: 20080182900Abstract: Medicaments containing shikonin compounds and salts thereof including shikonin and alkannin are used for treatment of virus infections, mycoplasma infections and malignant tumor.Type: ApplicationFiled: September 26, 2007Publication date: July 31, 2008Inventor: Feixin Wang
-
Publication number: 20080171085Abstract: A novel biphasic pharmaceutial or nutraceutical composition delivers both an immediate and a sustained dose of a pharmaceutical or nutraceutical agent in the same unit dose. An oral unit dose of melatonin includes melatonin in a sustained-release matrix contained in a solid phase, such as a tablet of capsule, and also includes melatonin in a film dispersed on the surface of the solid phase. Approximately 80 to 90 weight percent of the total amount of melatonin of each unit is contained in the sustained-release matrix and the remainder in the film. The novel composition permits a mammal, including a human being, to both rapidly fall asleep and remain asleep for a desired period of time by releasing an immediate-release dose and a sustained-release dose of melatonin.Type: ApplicationFiled: January 11, 2007Publication date: July 17, 2008Inventors: Dahlia Elnekave, Gopi Mohan Sundaram, Michael Todd Yatcilla
-
Patent number: 7288680Abstract: The present invention provides novel benzotropolone derivatives represented by the general formula: including neotheaflavate B and EGCGCa. The benzotropolone derivatives of the present invention are effective antioxidant and anti-inflammatory agents. The present invention also provides novel method of synthesizing benzotropolone compounds in high yields and method of treating inflammatory conditions using benzotropolone containing compounds.Type: GrantFiled: June 23, 2006Date of Patent: October 30, 2007Assignees: Wellgen, Inc., Rutgers, The State University of New JerseyInventors: Chi-Tang Ho, Geetha Ghai, Shengmin Sang, Jin-Woo Jhoo, Mou-Tuan Huang, Robert T. Rosen, Slavik Dushenkov
-
Patent number: 7256219Abstract: The present invention is directed to multifluoro-substituted Chalcones and analogs thereof, represented by the general Formula I: wherein Ar and R6-R10 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: March 14, 2002Date of Patent: August 14, 2007Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, P. Sanjeeva Reddy, John A. Drewe, Bao Ngoc Nguyen, Shailaja Kasibhatla
-
Patent number: 7163930Abstract: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.Type: GrantFiled: October 5, 2004Date of Patent: January 16, 2007Assignee: The University of British ColumbiaInventors: John K. Jackson, Helen M. Burt
-
Patent number: 7138433Abstract: With an object of providing an agent for treating hepatic disease by inhibiting occurrence of hepatic disease, in particular portal venous invasion, there is disclosed an agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof. This agent for treating or preventing hepatic disease is effective against hepatic cancer, in particular DCP (des-?-carboxy prothrombin) positive hepatic cancer. Moreover, the agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof according to the present invention exhibits remarkable effects in improving the prognosis after hepatic cancer treatment, and exhibits excellent effects as an agent for inhibiting the recurrence of hepatic cancer.Type: GrantFiled: September 16, 2003Date of Patent: November 21, 2006Assignee: Eisai Co., Ltd.Inventors: Yukihiro Koike, Yasushi Shiratori, Masao Omata, Toshihiko Mizuta, Kyosuke Yamamoto
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 7091241Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.Type: GrantFiled: June 3, 2002Date of Patent: August 15, 2006Assignee: Summa Health SystemInventors: Jacques Gilloteaux, Henryk S. Taper, James M Jamison, Jack L. Summers
-
Patent number: 7087790Abstract: The present invention provides novel benzotropolone derivatives represented by the general formula: including neotheaflavate B and EGCGCa. The benzotropolone derivatives of the present invention are effective antioxidant and anti-inflammatory agents. The present invention also provides novel method of synthesizing benzotropolone compounds in high yields and method of treating inflammatory conditions using benzotropolone containing compounds.Type: GrantFiled: August 29, 2003Date of Patent: August 8, 2006Assignee: Rutgers, The State University of New JerseyInventors: Chi-Tang Ho, Geetha Ghai, Shengmin Sang, Jin-Woo Jhoo, Mou-Tuan Huang, Robert T. Rosen, Slavik Dushenkov
-
Patent number: 7060686Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.Type: GrantFiled: August 2, 2004Date of Patent: June 13, 2006Assignees: The Regents of the University of California, Florida Atlantic University Board of TrusteesInventors: Robert S. Jacobs, Russell G. Kerr
-
Patent number: 6987127Abstract: Malignant melanoma cells spontaneously generate reactive oxygen species (ROS) that promote constitutive activation of the transcription factor nuclear factor-kB (NF-kB). Although antioxidants and inhibitors of NAD(P)H oxidases significantly reduce constitutive NF-kB activation and suppress cell proliferation, the nature of the enzyme responsible for ROS production in melanoma cells has not been determined. To address this issue, we now have characterized the source of ROS production in melanoma cells. ROS are generated by isolated, cytosol-free melanoma plasma membranes, with inhibition by NAD(P)H oxidase inhibitors. The p22phox, gp91phox and p67phox components of the human phagocyte NAD(P)H oxidase, and the 91phox homolog NOX4 were demon-strated in melanomas by RT-PCR and sequencing, and protein product for both p22phox and gp91phox were detected in cell membranes by immunoassay. Normal human epidermal melanocytes expressed only p22phox and NOX4.Type: GrantFiled: December 19, 2002Date of Patent: January 17, 2006Assignee: Charlotte-Mecklenburg Hospital AuthorityInventor: Thomas Preston Kennedy
-
Patent number: 6984389Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: GrantFiled: December 16, 2002Date of Patent: January 10, 2006Assignee: University of Connecticut Health CenterInventor: Zihai Li
-
Patent number: 6956061Abstract: The present invention relates to compounds of the formula (I): which are produced by the plant Garcinia punctata, chemical derivatives derived therefrom, a process for their preparation, and their use as pharmaceuticals, in particular for the treatment and/or prophylaxis of bacterial infectious diseases.Type: GrantFiled: July 31, 2003Date of Patent: October 18, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Matthias Schiell, Michael Kurz, Sabine Haag-Richter
-
Patent number: 6946492Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-one systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in methods of embodiments of the invention may include compounds of the formula in which the radicals are as defined, and their physiologically acceptable salts.Type: GrantFiled: August 30, 2002Date of Patent: September 20, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6887904Abstract: Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.Type: GrantFiled: December 4, 2002Date of Patent: May 3, 2005Assignee: Aventis Pharma S. A.Inventors: Patrick Mailliet, Marc Capet, Gilles Tiraboschi, Thomas Caulfield
-
Patent number: 6855696Abstract: The present invention provides illudin analogs of the general formula I: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I.Type: GrantFiled: November 5, 2001Date of Patent: February 15, 2005Assignee: The Regents of the University of CaliforniaInventors: Trevor C. McMorris, Michael J. Kelner
-
Patent number: 6794415Abstract: A method of treating osteoporosis in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount to treat osteoporosis of a compound selected from the group consisting of a compound of the formula: wherein the substituents are defined as in the Specification.Type: GrantFiled: July 8, 2002Date of Patent: September 21, 2004Assignee: Aventis Pharma S.A.Inventors: Dominique Lesuisse, Jean-Georges Teutsch
-
Patent number: 6790463Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.Type: GrantFiled: March 30, 2001Date of Patent: September 14, 2004Inventors: Robert F. Hofmann, Robert H. Carpenter
-
Patent number: 6787571Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.Type: GrantFiled: November 27, 2001Date of Patent: September 7, 2004Assignees: The Regents of the University of California, Florida Atlantic University Board of trusteesInventors: Robert S. Jacobs, Russell G. Kerr
-
Patent number: 6787672Abstract: This invention pertains to substituted chalcones, specifically substituted 1-(4-methoxyphenyl)-3-(3,5-dimethoxyphenyl)prop-1-en-3-ones, which have therapeutic application, for example, as potent antiproliferative agents and antiinflammatory agents, and which have the formula (I) wherein: X is —H, —OH, —OC(═O)R3, —OS(═O)2OH, or —OP(═O)(OH)2; Y is —H or a C1-4alkyl group; Z is —H or —OCH3; R1 is —H, a C1-4alkyl group, or C1-4fluoroalkyl group; R2 is —H, a C1-4alkyl group, or C1-4fluoroalkyl group; and, R3 is —H, a C1-6alkyl group, a C3-20 heterocyclyl group, or a C5-20aryl group; and pharmaceutically acceptable salts, esters, and protected forms thereof.Type: GrantFiled: September 26, 2002Date of Patent: September 7, 2004Assignee: Cancer Research Technology LimitedInventors: Gerard Andrew Potter, Paul Crispin Butler, Elugba Wanogho
-
Patent number: 6777424Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.Type: GrantFiled: September 19, 2001Date of Patent: August 17, 2004Assignee: Pfizer Inc.Inventor: Bruce H. Littman
-
Patent number: 6777447Abstract: Benzylidene cyclohexanone, cyclopentanone and acteone derivatives and therapeutic methods of using same are disclosed. The compounds are non-toxic and exhibit potent anti-inflammatory, antibacterial and antioxidation activity. Also, certain compounds of the invention inhibit glutathione S-transferase (“GST”), but do not irritate the gastrointestinal tract. Pharmaceutical compositions containing the compounds of the invention and pharmaceutically acceptable carriers are also disclosed.Type: GrantFiled: February 27, 2002Date of Patent: August 17, 2004Inventors: Mochammad Samhoedi Reksohadiprodjo, Henk Timmerman, Sardjiman Dummy, Supardjan Amir Margono, Sudibyo Martono, Sugiyanto Dummy, Lukman Rahman Hakim, Nurlaila Dummy, Arief Rahman Hakim, Ika Puspitasari, Arief Nurrochmad, Purwantiningsih Dummy, Oetari Dummy, Tedjo Yuwono
-
Patent number: 6773727Abstract: Low concentrations of gossypol and related phyllophage toxins from cotton improve the effectiveness of insecticidal agents against social insects, including cockroaches, and particularly termites and ants. Levels of gossypol and other cotton phyllophage toxins which are sufficiently low as to be non-biocidal to social insects alone, will significantly increase the control efficacy of other insecticidal agents. Consequently, use of these low levels of these cotton phyllophage toxins allows the levels of insecticidal agents necessary for effectively controlling the insects to be significantly reduced relative to applications without cotton phyllophage toxins. Furthermore, insecticidal agents which are normally ineffective for control of social insects when used alone, may be effective when used in conjunction with the cotton phyllophage toxins.Type: GrantFiled: August 13, 2001Date of Patent: August 10, 2004Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Maria G. Rojas, Juan A. Morales-Ramos, Peter J. Wan
-
Patent number: 6761912Abstract: A composition and a method for administering an improved supplement to prevent bone density loss. The composition combines a calcium compound with inulin, and optionally magnesium, Vitamin D3, Vitamin K, Vitamin C, and may combine a soy isoflavone, all in a dietary acceptable form in a beverage, a beverage preparation, a paste, a bar, or a cookie.Type: GrantFiled: October 25, 2001Date of Patent: July 13, 2004Assignee: Pharmavite LLCInventors: Samuel L. Forusz, Hanlan Liu, Rose M. Muatine
-
Publication number: 20040082662Abstract: The present invention relates to compounds of the formula (I) 1Type: ApplicationFiled: July 31, 2003Publication date: April 29, 2004Applicant: Aventis Pharma Deutschland GmbhInventors: Matthias Schiell, Michael Kurz, Sabine Haag-Richter
-
Patent number: 6706713Abstract: This invention relates to the use of a conjugate comprising an active substance and a native protein which is not recognized as foreign protein for the production of a pharmaceutical preparation for treating and/or diagnosing inflammatory, infectious and/or skin diseases.Type: GrantFiled: October 14, 1997Date of Patent: March 16, 2004Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Hansjörg Sinn, Hans-Hermann Schrenk, Wolfgang Maier-Borst, Gerd Stehle
-
Patent number: 6696484Abstract: Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5&agr;-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5&agr;-reductase inhibitor compounds is also contemplated.Type: GrantFiled: April 24, 2002Date of Patent: February 24, 2004Assignee: University of Chicago Office of Technology and Intellectual PropertyInventors: Shutsung Liao, Richard Hiipakka